| 產品名稱 | TDZD 8 |
| 產品貨號 | Axon 2010 CAS [327036-89-5] MF C10H10N2O2SMW 222.26 Purity: 98% Soluble in DMSO Description Selective and non-ATP-competitive inhibitor of glycogen synthase kinase-3β (GSK-3β); potential agent for the treatment of Alzheimer's disease References Certificates Categories Extra info AA Martinez et al.First non-ATP competitive glycogen synthase kinase 3 beta (GSK-3beta) inhibitors: thiadiazolidinones (TDZD) as potential drugs for the treatment of Alzheimer's disease. J.?Med. Chem. 2002, 45(6), 1292-1299. ? M Collino et al. Treatment with the glycogen synthase kinase-3beta inhibitor, TDZD-8, affects transient cerebral ischemia/reperfusion injury in the rat hippocampus. Shock. 2008, 30(3), 299-307.? ? D Aguilar-Morante et al. Inhibition of Glioblastoma Growth by the Thiadiazolidinone Compound TDZD-8. PLoS ONE 2010, 5(11), e13879.? Certificate of Analysis Material Safety Data Sheet CNS Diabetes & Metabolism Immunology Pain & Inflammation Stem Cell GSK-3 Wnt-β-Catenin PI3K-Akt-mTOR EC 2.7.11.26 Selective and non-ATP-competitive inhibitor of GSK-3β Chemical name 4-benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione Parent CAS No. [327036-89-5] Order Size Unit Price Stock 10 mg €90.00 In Stock |
| 產品價格 | 現(xiàn)貨詢價，電話：010-67529703 |
| 產品規(guī)格 | |
| 產品品牌 | axonmedchem |
| 產品概述 | |
| 產品詳情 |
TDZD 8Axon 2010 CAS [327036-89-5] MF C10H10N2O2S
Description
Selective and non-ATP-competitive inhibitor of glycogen synthase kinase-3β (GSK-3β); potential agent for the treatment of Alzheimer's disease
Selective and non-ATP-competitive inhibitor of GSK-3β
Chemical name4-benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione Parent CAS No.[327036-89-5] |
| 產品資料 |
